Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PDE8B | O95263 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282976 | 1.00 | POLB (0.51) | POLBL3MBTL1PDE8BKDM1AHSD17B10 | |
| SCHEMBL282977 | 1.00 | POLB (0.51) | POLBL3MBTL1PDE8BKDM1AHSD17B10 | |
| SCHEMBL31048468 | 0.98 | POLB (0.50) | POLBL3MBTL1PDE8BKDM1AHSD17B10 | |
| SCHEMBL31323435 | 0.98 | POLB (0.50) | POLBL3MBTL1PDE8BKDM1AHSD17B10 | |
| SCHEMBL20399730 | 0.98 | POLB (0.50) | POLBL3MBTL1PDE8BKDM1AHSD17B10 | |
| SCHEMBL135177 | 0.95 | L3MBTL1 (0.58) | POLBL3MBTL1PDE8BHSD17B10ATM | |
| SCHEMBL133363 | 0.95 | L3MBTL1 (0.58) | POLBL3MBTL1PDE8BHSD17B10ATM | |
| SCHEMBL47049 | 0.95 | L3MBTL1 (0.58) | POLBL3MBTL1PDE8BHSD17B10ATM | |
| SCHEMBL3769601 | 0.91 | HPGD (0.54) | POLBL3MBTL1PDE8BHSD17B10HPGD | |
| SCHEMBL3769598 | 0.91 | HPGD (0.54) | POLBL3MBTL1PDE8BHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | BRIDGE MEDICINES (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025226861-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4236937-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4583869-A2 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | Bridge Medicines (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12312370-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| EP-4217361-B1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | GREY WOLF THERAPEUTICS LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240300976-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | Grey Wolf Therapeutics Limited (GB) | 2024-09-12 | — | — | US | disclosed |
| EP-1950610-A1 | COMPOSITION FOR FORMING UPPER FILM AND METHOD FOR FORMING PHOTORESIST PATTERN | JSR Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| US-7402684-B2 | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENECTICS EHF. (IS) | 2008-07-22 | — | — | US | disclosed |
| EP-1926708-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | Decode Chemistry, Inc. (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007040681-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040682-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
| WO-1991000724-A1 | ALKYNYL AMINES THAT REGULATE CHOLINERGIC NEUROTRANSMISSION | ABBOTT LABORATORIES (US) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | POLB 1188/4885L3MBTL1 3582/4885PDE8B 4853/4885 |
| US-20240376090-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | HTR2A, HTR5A, HTR1A | POLB 4123/4885L3MBTL1 4631/4885PDE8B 444/4885 |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | POLB 2277/4885L3MBTL1 1534/4885PDE8B 2500/4885 |
| US-12312370-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | POLB 692/4885L3MBTL1 3263/4885PDE8B 3177/4885 |
| US-20240300976-A1 | COMPOUNDS AS MODULATORS OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 1 (ERAP1) | ERAP1, ERAP2, ERMP1 | POLB 4759/4885L3MBTL1 2377/4885PDE8B 4639/4885 |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | POLB 2277/4885L3MBTL1 1534/4885PDE8B 2500/4885 |
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | MLLT3, MLLT1, FLT3 | POLB 4206/4885L3MBTL1 170/4885PDE8B 4750/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | POLB 4774/4885L3MBTL1 274/4885PDE8B 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.